Moreover, IL-6 was observed to increase miR-17 and miR-19a, target TLR7 and tumor necrosis factor alpha (TNF-α) messenger RNA, and provoke a condition of tolerance to TLR7 agonists in B-CLL cells. This evidence concerns the gene TNF and B-cell chronic lymphocytic leukemia.